|
Free Research Report Download:
The Cancer Market Outlook To 2014
Free Pharmaceutical Market Research Reports
Biotechnology
Corporate & Fiscal
Drug Delivery
Health Products
Hospital Markets
Indication Areas
Medical Devices
Prescription Medicines
R&D
Custom Research
Pharmaceutical Events & Conferences
Contact
Terms & Conditions
Privacy
Business Market Research
Energy Market Research
Financial Market Research
Pharmaceutical Market Research
Telecoms Market Research
|
Home > Market Research > Biotechnology > Epigenomics: Emerging Opportunities in Biomarkers, Diagnostics and Therapeutics -
INTRODUCTION
STUDY GOALS AND OBJECTIVES
BCC’s goal for this study was to examine the status of commercial epigenomics technologies and products and assess their worldwide growth potential over a 5-year period from 2009 to 2014. We analyzed the four important market segments for epigenomics: research tools, diagnostics, therapeutics, and assays for cellular therapies. Our objective was to present a comprehensive discussion of where the state-of-the-art is in epigenomics technologies and the current and future commercial potential for these key market segments. We also wanted to study current large-scale epigenome funding projects as well as the industry competitive and patent dynamics. REASONS FOR DOING THE STUDY Epigenomics is a fast-growing biology field that is rapidly commercializing. Epigenomics research tools and products enable discovery of novel diagnostic biomarkers and drug targets. We previously examined the epigenetics market in 2007. Since that time, the FDA approved several epigenetic drugs for treating non-Hodgkin’s lymphomas and myelodysplastic syndromes. In the past 2 years, several epigenetic-based in-vitro diagnostics tests have been launched in the United States and Europe for early colon cancer detection. A significant number of additional drug candidates and diagnostics tests are in the clinical pipeline and ready to be commercialized during our forecast horizon. We are interested in determining the particular diseases for which epigenomic-based diagnostics products will be used and the market and growth potential for these applications. We are also interested in understanding the scope of the future market potential for epigenetic drugs, including DNA methylase inhibitors and histone deacetylase inhibitors. It is particularly timely to examine the epigenomics industry in 2010 given the changes in the industry and the increasing importance of gene regulation beyond DNA sequence. INTENDED AUDIENCE We have compiled a study of important epigenomics technologies used in the four major applications of research tools, diagnostics, therapeutics, and cellular therapies. We define and describe the fundamental epigenomic technologies, the market driving forces, product types, main market applications, key companies, strategic alliances and acquisitions, future global market potential and product sales forecasts for the period 2009 through 2014. We analyze in detail the clinical pipelines for both epigenetic-based diagnostics and therapeutics. This study will be of particular interest to the molecular diagnostics industry, pharmaceutical manufacturers, biotechnology companies, and life science research tools companies. It will also be of interest to companies involved in drug and/or biomarker discovery programs; manufacturers of microarrays or next generation sequencing systems, high-grade antibodies, restriction enzymes or primers; bioinformatics developers, and cancer researchers and clinicians. SCOPE OF REPORT The study scope includes the major epigenomics technologies that are now, or likely to become, commercialized within the next 5 years. We examine the products flowing from these technologies, market segments into which these products are sold, and we forecast product sales for the period 2009 through 2014. We describe factors that are driving growth in these markets. Competitive dynamics and key trends in each of the market segments are discussed. We examine the strategies of successful companies, strategic alliances, and the impact that large-scale epigenomic projects have on the industry. We profile the major companies in the industry. The scope of our analysis includes DNA methylation and histone acetylation and methylation technologies; and the important market segments within research tools, diagnostics, therapies, and cellular therapeutics. We are particularly interested in cancer indications, which comprise the bulk of the diagnostics and therapies markets. METHODOLOGY Both primary and secondary research methodologies were used in preparing this market research report. Included is an analysis of each of the four key market segments that will be commercially important during the next 5 years: research tools, cancer diagnostics, cancer therapeutics, and cellular therapies. We examine each the important product types within these market segments, and estimate the current and future sales from this perspective. We provide sales revenue for 2008, 2009, and forecast growth through 2014 for each of these segments. For each of the market segments, we present market information for the important products and technologies. For drugs and diagnostics, we present market information by indication and by technology. For research tools, we present market information by technology format and product type.
Top of Page
Table of Contents
- CHAPTER ONE: INTRODUCTION
- STUDY GOALS AND OBJECTIVES
- REASONS FOR DOING THE STUDY
- INTENDED AUDIENCE
- SCOPE OF REPORT
- METHODOLOGY
- INFORMATION SOURCES
- RELATED BCC REPORTS
- BCC ONLINE SERVICES
- DISCLAIMER
- CHAPTER TWO: SUMMARY
- SUMMARY
- SUMMARY TABLE GLOBAL VALUE OF EPIGENOMIC PRODUCTS, BY APPLICATION, THROUGH 2014 ($ MILLIONS)
- SUMMARY FIGURE GLOBAL VALUE OF EPIGENOMIC PRODUCTS, BY APPLICATION, 2008-2014 ($ MILLIONS)
- CHAPTER THREE: OVERVIEW
- INTRODUCTION
- THE NEW PARADIGM OF EPIGENOMICS
- FIGURE 1 EPIGENOMICS: A NEW PARADIGM
- HOW EPIGENOMICS FITS WITHIN GENOMICS
- TABLE 1 GENOMICS PLATFORMS
- TECHNICAL SCOPE OF THIS REPORT
- TABLE 2 TECHNOLOGY SCOPE OF THIS REPORT
- MARKET POTENTIAL OF EPIGENOMICS
- TABLE 3 GLOBAL VALUE OF EPIGENOMIC PRODUCTS, BY APPLICATION, THROUGH 2014 ($ MILLIONS)
- EPIGENOMICS PRODUCTS
- RESEARCH TOOLS AND REAGENTS
- DIAGNOSTICS
- DRUGS
- FIGURE 2 ACTIVE CANCER EPIGENETIC DRUG CLINICAL TRIALS, BY PHASE AND INDICATION, JANUARY 2010
- GROWTH DRIVING FORCES
- GROWTH IN LIFE SCIENCE FUNDING
- CREATION OF EPIGENOMIC MAPS
- AGING POPULATION IN DEVELOPED COUNTRIES
- NEED FOR BETTER CANCER THERAPIES
- GROWTH IN PERSONALIZED MEDICINE
- WHY EPIGENETIC TECHNOLOGY IS IMPORTANT
- FIGURE 3 EPIGENETIC PROCESSES CAN GENERATE ABNORMAL CELLS DURING CELL DEVELOPMENT
- LIFE CYCLE STATUS OF EPIGENOMICS TECHNOLOGIES
- HISTORICAL BACKGROUND
- TABLE 4 HISTORICAL OVERVIEW OF EPIGENOMICS
- THE EPIGENOMICS INDUSTRY
- TABLE 5 EPIGENOMICS INDUSTRY KEY COMPANIES
- CHAPTER FOUR: EPIGENETIC TECHNOLOGIES
- INTRODUCTION
- EPIGENETIC ANALYSIS TECHNOLOGIES
- TABLE 6 EPIGENETIC ANALYSIS TECHNOLOGIES
- STATUS OF DNA AND HISTONE ANALYSIS TECHNOLOGIES
- TABLE 7 STATUS OF DNA METHYLATION AND HISTONE ANALYSIS TECHNOLOGIES
- DNA AND HISTONE ANALYSIS WORKFLOW
- FIGURE 4 UPSTREAM AND DOWNSTREAM STEPS IN EPIGENETIC ANALYSIS WORKFLOW
- DNA METHYLATION
- METHYLATED CYTOSINE—A FIFTH BASE
- FIGURE 5 EPIGENETIC CHANGES TO DNA AFFECT GENE EXPRESSION
- BIOLOGICAL ROLE OF DNA METHYLATION
- TABLE 8 BIOLOGICAL ROLES OF DNA METHYLATION
- DNA METHYLTRANSFERASE ENZYMES
- CPG ISLANDS
- TABLE 9 DESCRIPTION OF CPG ISLANDS
- HISTONE METHYLATION AND ACETYLATION
- HISTONES
- HISTONE MODIFICATIONS
- FIGURE 6 ACETYLATION OF HISTONE TAIL REGIONS
- HISTONE ACETYLATION AND METHYLATION ENZYMES
- FIGURE 7 HISTONE ACETYLATION AND METHYLATION ENZYMES
- Histone Acetyl Transferases (HAT)
- Histone Deacetylases (HDAC)
- TABLE 10 HDAC ENZYMES CLASSES
- Histone Methyltransferases and Demethylases
- INAPPROPRIATE METHYLATION AND ACETYLATION
- TABLE 11 MECHANISMS FOR INAPPROPRIATE METHYLATION AND ACETYLATION
- CHAPTER FIVE: EPIGENOMIC ANALYSIS TECHNOLOGIES
- IMPORTANCE OF EPIGENOMIC RESEARCH TOOLS
- DNA METHYLATION RESEARCH TOOLS
- TABLE 12 DNA METHYLATION ANALYSIS ASSAYS
- TABLE 13 EMERGING DNA METHYLATION TECHNOLOGIES
- TABLE 14 ACROYNMS FOR DNA METHYLATION TECHNOLOGIES
- DNA METHYLATION ANALYSIS WORKFLOW
- FIGURE 8 METHYLATED DNA ANALYSIS WORKFLOW
- DNA METHYLATION ANALYSIS METHODS BY COVERAGE AND THROUGHPUT
- TABLE 15 DNA METHYLATION TECHNOLOGIES BY COVERAGE AND THROUGHPUT
- DNA METHYLATION ANALYSIS TYPES BY WORKFLOW
- TABLE 16 EXAMPLES OF DNA METHYLATION ASSAYS
- DNA METHYLATION ANALYSIS: UPSTREAM TECHNOLOGIES
- TABLE 17 METHYLATION RECOGNITION TECHNOLOGIES
- RESTRICTION ENZYME-BASED METHODS
- FIGURE 9 ANALYSIS OF DNA METHYLATION BY RESTRICTION ENZYMES
- BISULFITE-BASED METHODS
- Bisulfite-based Methods (Continued)
- FIGURE 10 BISULFITE CONVERSION OF DNA
- Analysis of Low Complexity DNA
- AFFINITY-BASED METHODS
- CHALLENGE OF HIGH BACKGROUND METHYLATED DNA
- GENOME WIDE DNA METHYLATION ANALYSIS
- TABLE 18 DNA METHYLATION ANALYSIS TECHNIQUES BY GENOME RESOLUTION
- HISTONE EPIGENETIC ANALYSIS TECHNOLOGIES
- TABLE 19 CHIP ASSAYS
- CHIP-CHIP AND CHIP-SEQ
- FIGURE 11 WORKFLOW SCHEMATIC FOR CHIP PLATFORMS
- TABLE 20 TECHNOLOGIES FOR MAPPING GENOMIC LOCATION OF CHROMATIN PROTEINS AND ENZYMES
- EMERGING DOWNSTREAM EPIGENETIC ANALYSIS PLATFORMS
- MICROARRAYS
- TABLE 21 MICROARRAY TYPES
- TABLE 22 COMPARISON OF DNA AND PROTEIN MICROARRAY TECHNOLOGIES
- DNA Microarray Technologies
- FIGURE 12 MICROARRAY FEATURE DENSITY
- FIGURE 13 MICROARRAY RESOLUTION
- TABLE 23 MICROARRAY GENOME CONTENT
- TABLE 24 DNA MICROARRAY PLATFORM FEATURES
- TABLE 25 DNA MICROARRAY PLATFORM COMPARISON FOR MAJOR MANUFACTURERS
- Microarrays for Epigenetics Analysis
- FIGURE 14 MICROARRAYS ENHANCE MULTIPLEX CAPABILITIES OF EPIGENETICS ASSAYS
- NEXT GENERATION DNA SEQUENCING
- FIGURE 15 DNA SEQUENCING PLATFORMS
- FIGURE 16 NEXT GENERATION SEQUENCING TECHNOLOGIES WORKFLOW OVERVIEW
- SERIAL ANALYSIS OF GENE EXPRESSION
- ANTIBODIES
- ALTERNATIVES TO ANTIBODIES IN UPSTREAM ANALYSIS
- STEP
- CHAPTER SIX: EPIGENETICS DIAGNOSTICS TECHNOLOGIES
- WHAT IS A BIOMARKER?
- TABLE 26 ROLE OF BIOMARKERS IN CLINICAL TRIAL DESIGN
- DNA METHYLATION AS A CANCER BIOMARKER
- DNA METHYLATION IN CANCER ETIOLOGY
- TABLE 27 BIOLOGICAL RATIONALE FOR DNA METHYLATION CANCER BIOMARKERS
- TABLE 28 CANCER-RELATED CELL PATHWAYS AND GENES AFFECTED BY HYPER-METHYLATION
- Cell Cycle Control
- Cell Invasion and Adhesion
- DNA Damage Repair
- Growth Factor Response
- Regulation of Apoptosis
- Hormonal Response
- Cytokine Signaling
- TABLE 29 CANCER-RELATED EPIGENETIC CHANGES
- COMPARISON OF MOLECULAR BIOMARKER PLATFORMS
- TABLE 30 COMPARISON OF KEY CANCER BIOMARKER TECHNOLOGY PLATFORMS
- ASSESSMENT OF DNA METHYLATION BIOMARKER COMPETITIVE POSITION
- EPIGENETIC BIOMARKER GENES
- TABLE 31 PUBLISHED DNA METHYLATION BIOMARKER GENES FOR CANCERS
- TABLE 32 DIFFERENTIALLY METHYLATED GENES IN NEUROLOGIC AND CARDIOVASCULAR DISORDERS
- BIOMARKER DISCOVERY PROCESS
- METHYLATION BIOMARKER DISCOVERY TECHNOLOGIES
- TABLE 33 DNA METHYLATION ANALYSIS TECHNOLOGIES IN BIOMARKER DISCOVERY
- GENOME-WIDE SCANNING FOR BIOMARKER DISCOVERY
- CASE STUDY: FROM RESEARCH TOOLS TO BIOMARKERS
- IN-VITRO DIAGNOSTIC DEVELOPMENT PROCESS
- PHASE 1: BIOMARKER DISCOVERY
- PHASE 2: BIOMARKER VALIDATION
- PHASE 3: FORMAL KIT DEVELOPMENT
- PHASE 4: CLINICAL VALIDATION
- PHASE 5: REGULATORY REVIEW AND APPROVAL
- FUTURE STATUS OF DNA METHYLATION BIOMARKERS
- TABLE 34 TECHNICAL HURDLES FOR DEVELOPMENT OF METHYLATION EPIGENETIC CANCER BIOMARKERS
- CHAPTER SEVEN: EPIGENETIC CANCER DRUG TECHNOLOGIES
- INTRODUCTION
- EPIGENETICS IN TUMORIGENESIS
- EPIGENETIC GENES IN HUMAN CANCER
- TABLE 35 EPIGENETIC GENES ALTERED IN HUMAN CANCERS
- EPIGENETIC ENZYME DRUG TARGETS
- FIGURE 17 HISTONE DEACETYLASE REACTION
- TABLE 36 STATUS OF INHIBITORS OF EPIGENETIC ENZYMES TARGETING HISTONES
- HISTONE DEACETYLASE INHIBITORS
- BENEFITS OF HDAC INHIBITORS
- HDAC INHIBITOR DRUG CLASSES
- TABLE 37 HDAC INHIBITOR CLASSES AND RELATIVE POTENCY
- Hydroxamates
- FIGURE 18 CHEMICAL STRUCTURE OF TRICHOSTATIN A, A HYDROXAMATE CLASS HDAC INHIBITOR
- Aliphatic Acids
- FIGURE 19 PHENYLBUTYRIC ACID, AN ALIPHATIC ACID CLASS HDAC INHIBITOR
- Cyclic Tetrapeptides
- FIGURE 20 APICIDIN A, A CYCLIC TETRAPEPTIDE CLASS HDAC INHIBITOR
- Benzamides
- FIGURE 21 ENTINOSTAT, A BENZAMIDE CLASS HDAC INHIBITOR
- HDAC INHIBITOR TECHNOLOGY TRENDS
- TABLE 38 HDAC INHIBITOR DRUG TECHNOLOGY TRENDS
- Enzyme Selectivity
- TABLE 39 HDAC INHIBITOR CLASS I AND II SELECTIVITY
- Potency
- Improvements in Drug-like Properties
- SELECTIVE HDAC COMPOUNDS CAN PROVIDE COMPETITIVE ADVANTAGE
- FIGURE 22 DISEASE HDAC ISOFORM GENE EXPRESSION PROFILE
- CHEMICAL DESIGN IS THE KEY TO HDAC INHIBITOR SELECTIVITY
- FIGURE 23 COMMON STRUCTURAL COMPONENT MOTIFS OF VORINOSTAT
- HDAC INHIBITORS IN COMBINATION THERAPIES
- TABLE 40 DRUG CLASSES THAT CAN BE USED IN COMBINATION WITH HDAC INHIBITORS
- HDAC INHIBITORS AS THERAPIES OUTSIDE CANCER
- DERMATOLOGICAL DISORDERS
- PARASITIC DISEASES
- NEURODEGENERATIVE DISEASES
- DIABETES
- INFLAMMATORY DISEASES
- IMMUNE DISORDERS
- DNA METHYLTRANSFERASE INHIBITORS
- FIGURE 24 LEAD DNMT INHIBITOR COMPOUNDS
- TECHNICAL CHALLENGES FOR EPIGENETIC DRUG DEVELOPMENT
- TABLE 41 FUTURE CHALLENGES FOR EPIGENETIC DRUG
- DEVELOPMENT
- CHAPTER EIGHT: EPIGENETICS CLONING AND CELLULAR THERAPIES TECHNOLOGIES
- SOMATIC CELL NUCLEAR TRANSFER
- FIGURE 25 SOMATIC CELL NUCLEAR TRANSFER
- TABLE 42 TECHNOLOGY OPPORTUNITIES IN SOMATIC CELL NUCLEAR TRANSFER
- APPLICATIONS
- REPROGRAMMING FACTORS
- FIGURE 26 EPIGENETIC PROGRAMMING OF STEM CELLS
- QUALITY CONTROL ASSAYS IN CELLULAR THERAPIES
- Tissue Engineering
- Stem Cell Therapies
- Non-stem Cell Therapies
- CHAPTER NINE: LARGE SCALE REGIONAL EPIGENOMICS PROJECTS
- LARGE SCALE REGIONAL EPIGENOMICS PROJECTS
- TABLE 43 REGIONAL EPIGENOMICS INITIATIVES
- EUROPE
- UNITED STATES
- ASIA
- CHAPTER TEN: CANCER DIAGNOSTICS APPLICATIONS
- ATTRACTIVE CANCER INDICATIONS FOR SCREENING MARKETS
- FIGURE 27 CANCER SCREENING OPPORTUNITY MATRIX FOR MOLECULAR DIAGNOSTICS
- EPIGENETICS AS A SCREENING PLATFORM
- FIGURE 28 NEW EPIGENETIC SCREENING PARADIGM
- DIAGNOSTIC SENSITIVITY AND SPECIFICITY
- FIGURE 29 SENSITIVITY AND SPECIFICITY
- STATUS OF DIAGNOSTICS TESTS FOR SELECTED CANCER INDICATIONS
- BLADDER CANCER
- CARCINOMA OF UNKNOWN PRIMARY (CUP)
- TABLE 44 COMMERCIAL MOLECULAR DIAGNOSTIC PLATFORMS FOR TISSUE OF ORIGIN TESTS
- CERVICAL CANCER
- TABLE 45 COMMERCIAL LANDSCAPE FOR HPV TESTS
- COLORECTAL CANCER
- Colorectal Cancer Existing Screening Tests
- TABLE 46 CURRENT SCREENING AND DIAGNOSTICS TESTS FOR COLORECTAL CANCER
- TABLE 47 ACCURACY OF EXISTING COLORECTAL SCREENING TESTS
- Molecular Colorectal Cancer Diagnostics Tests
- TABLE 48 COMMERCIAL LANDSCAPE FOR COLORECTAL MOLECULAR TESTS
- TABLE 49 COMPETITIVE SITUATION FOR CONVENTIONAL AND MOLECULAR COLON CANCER SCREENING TESTS
- Colorectal Cancer Diagnostics Tests
- GASTRIC CANCER
- LUNG CANCER
- OVARIAN CANCER
- TABLE 50 OVARIAN CANCER SCREENING TESTS
- TABLE 51 OVARIAN CANCER DIAGNOSTIC TEST STATUS
- PANCREATIC CANCER
- PEDIATRIC CANCERS
- PROSTATE CANCER
- PERSONALIZED TREATMENT EPIGENETIC-BASED TESTS
- KEY CLINICAL REQUIREMENTS FOR AN EPIGENETIC-BASED DIAGNOSTICS TEST
- TABLE 52 REQUIREMENTS FOR AN EPIGENETICS BISULFITE DIAGNOSTIC ASSAY
- DNA METHYLATION DIAGNOSTICS PIPELINE
- TABLE 53 EPIGENETIC DIAGNOSTICS DEVELOPMENT PIPELINE
- CHAPTER ELEVEN: THERAPEUTIC APPLICATIONS
- EPIGENETIC DRUG CLINICAL TRIALS
- TABLE 54 APPROVED EPIGENETIC DRUGS
- TABLE 55 NEXT GENERATION EPIGENETIC DRUGS
- FIGURE 30 ACTIVE CANCER EPIGENETIC DRUG CLINICAL TRIALS, BY DRUG CLASS AND CANCER TYPE, JANUARY 2010
- FIGURE 31 ACTIVE CANCER EPIGENETIC DRUG CLINICAL TRIALS, BY PHASE AND INDICATION, JANUARY 2010
- FIGURE 32 CURRENT EPIGENETIC CANCER DRUG CLINICAL TRIALS, BY DRUG AND TRIAL TYPE, JANUARY 2010
- FIGURE 33 ACTIVE EPIGENETIC CANCER DRUG CLINICAL TRIALS, BY CLINICAL PHASE AND TRIAL TYPE, JANUARY 2010
- EPIGENETIC DRUG NOMENCLATURE
- TABLE 56 EPIGENETIC DRUG NOMENCLATURE TABLE
- HDAC INHIBITOR CLINICAL TRIALS
- TABLE 57 HDAC INHIBITOR CLINICAL TRIALS SUMMARY
- TABLE 58 MBCD0103 INHIBITS SELECTED HDAC ENZYMES
- DNMT INHIBITORS CLINICAL TRIALS
- TABLE 59 DNMT INHIBITOR CLINICAL TRIALS SUMMARY
- EPIGENETIC DRUGS FOR NON-CANCER INDICATIONS
- TABLE 60 EPIGENETIC NON-CANCER DRUG LANDSCAPE
- CHAPTER TWELVE: MARKET GROWTH DRIVING FORCES
- EPIGENETICS SCIENTIFIC PUBLICATIONS
- FIGURE 34 GROWTH IN SCIENTIFIC PUBLICATIONS RELATED TO EPIGENETICS (NUMBER OF PUBLICATIONS)
- GROWTH DRIVING FORCES
- TABLE 61 FORCES DRIVING EPIGENOMICS INDUSTRY GROWTH
- GROWTH IN FUNDING FOR LIFE-SCIENCE RESEARCH
- TABLE 62 STIMULUS FUNDING ALLOCATED TO UNITED STATES SCIENCE SPENDING
- FIGURE 35 ANNUAL NIH FUNDING BUDGET, 2000-2009 ($ MILIONS)
- CREATION OF EPIGENETIC MAPS
- RANGE OF OCCURRENCE OF EPIGENETIC CHANGES
- AGING POPULATIONS IN DEVELOPED COUNTRIES
- NEED FOR BETTER CANCER THERAPIES
- GROWTH IN PERSONALIZED MEDICINE
- UNDERSTANDING OF EPIGENETIC PROCESSES BEYOND CANCER
- CHAPTER THIRTEEN: MARKET ANALYSIS
- MARKET SUMMARY
- TABLE 63 GLOBAL VALUE OF EPIGENOMIC PRODUCTS, BY APPLICATION, THROUGH 2014 ($ MILLIONS)
- TABLE 64 GLOBAL VALUE OF EPIGENOMIC PRODUCTS, BY GEOGRAPHY, THROUGH 2014 ($ MILLIONS)
- RESEARCH TOOLS MARKETS
- GLOBAL SALES BY PRODUCT
- TABLE 65 GLOBAL VALUE OF EPIGENOMIC ANALYSIS RESEARCH TOOLS, BY PRODUCT TYPE, THROUGH 2014 ($ MILLIONS)
- Kits
- Reagents
- Microarrays and Next Gen Sequencing
- EPIGENOMIC KIT SALES BY TECHNOLOGY
- TABLE 66 GLOBAL VALUE OF EPIGENOMICS RESEARCH TOOLS KITS, BY TECHNOLOGY, THROUGH 2014 ($ MILLION)
- TABLE 67 GLOBAL VALUE OF EPIGENOMIC ANALYSIS KITS, BY FORMAT, THROUGH 2014 ($ MILLIONS)
- DNA METHYLATION ANALYSIS KIT MARKET
- TABLE 68 GLOBAL VALUE OF DNA METHYLATION RESEARCH TOOLS KITS, BY ANALYSIS OBJECTIVE, THROUGH 2014 ($ MILLIONS)
- TABLE 69 GLOBAL VALUE OF DNA METHYLATION RESEARCH TOOLS KITS, BY TECHNOLOGY, THROUGH 2014 ($ MILLIONS)
- TABLE 70 GLOBAL VALUE OF DNA METHYLATION SINGLE LOCI RESEARCH TOOLS KITS, BY TECHNOLOGY, THROUGH 2014 ($ MILLIONS)
- TABLE 71 GLOBAL VALUE OF DNA METHYLATION GENOME-WIDE RESEARCH TOOLS KITS BY TECHNOLOGY, THROUGH 2014 ($ MILLIONS)
- HISTONE ANALYSIS KIT MARKET
- TABLE 72 GLOBAL VALUE OF HISTONE ANALYSIS KITS, BY TECHNOLOGY FORMAT, THROUGH 2014 ($ MILLIONS)
- EPIGENETICS MICROARRAY MARKETS
- MICROARRAYS AND NEXT GEN SEQUENCING AS DOWNSTREAM TOOLS
- MICROARRAY MARKET
- TABLE 73 GLOBAL VALUE OF EPIGENOMIC MICROARRAYS, BY APPLICATION, THROUGH 2014 ($ MILLIONS)
- RESEARCH TOOLS REAGENTS MARKET
- TABLE 74 GLOBAL VALUE OF RESEARCH TOOLS EPIGENOMIC REAGENTS, BY TECHNOLOGY, THROUGH 2014 ($ MILLIONS)
- CHAPTER FOURTEEN: EPIGENOMIC DIAGNOSTICS MARKET
- OVERVIEW OF CANCER DIAGNOSTICS MARKET
- TABLE 75 VALUE OF GLOBAL MOLECULAR DIAGNOSTICS PRODUCTS, BY APPLICATION, THROUGH 2014 ($ MILLIONS)
- CANCER MOLECULAR DIAGNOSTICS GROWTH DRIVERS
- EPIGENETICS-BASED DIAGNOSTICS MARKETS
- TABLE 76 PROJECTED CHANGE IN AGE 65-PLUS POPULATION BY REGION (%)
- TABLE 77 U.S. CANCER INCIDENCE AND ESTIMATED TREATMENT DECISIONS, 2009
- TABLE 78 GLOBAL VALUE OF EPIGENETIC DIAGNOSTIC ASSAYS, BY APPLICATION, THROUGH 2014 ($ MILLIONS)
- TABLE 79 GLOBAL VALUE OF EPIGENETIC DIAGNOSTIC ASSAYS, BY CANCER INDICATION, THROUGH 2014 ($ MILLIONS)
- CHAPTER FIFTEEN: EPIGENETIC DRUGS MARKETS
- OVERVIEW
- CANCER DRUG MARKET GROWTH DRIVING FORCES
- CLINICAL PROOF OF PRINCIPLE OF EPIGENETIC DRUGS
- IS ESTABLISHED
- EPIGENETIC THERAPIES BEYOND CANCER
- EPIGENETIC DRUG MARKET SUMMARY
- TABLE 80 GLOBAL VALUE OF EPIGENETIC DRUGS, BY CANCER INDICATION, THROUGH 2014 ($ MILLIONS)
- Hematological
- Solid Tumors
- EPIGENETIC DRUG MARKET BY DRUG CLASS
- TABLE 81 GLOBAL VALUE OF EPIGENETIC DRUGS, BY DRUG CLASS, THROUGH 2014 ($ MILLIONS)
- HDAC INHIBITORS MARKETS
- Strategic Opportunities in HDAC Inhibitors
- TABLE 82 SUMMARY OF HDAC INHIBITOR STRATEGIC OPPORTUNITIES FOR CANCER TREATMENT
- HDAC Inhibitor Drug Market Size by Indication
- TABLE 83 GLOBAL VALUE OF HDAC INHIBITOR DRUGS, BY INDICATION, THROUGH 2014 ($ MILLIONS)
- HDAC Inhibitor Market Size by Technology
- TABLE 84 GLOBAL VALUE OF HDAC INHIBITOR DRUGS, BY TECHNOLOGY, THROUGH 2014 ($ MILLIONS)
- DNMT INHIBITORS MARKET
- TABLE 85 GLOBAL VALUE OF DNMT INHIBITOR DRUGS, BY INDICATION, THROUGH 2014 ($ MILLIONS)
- TABLE 86 GLOBAL VALUE OF DNMT INHIBITOR DRUGS, BY TECHNOLOGY, THROUGH 2014 ($ MILLIONS)
- HEMATOLOGICAL CANCER EPIGENETIC DRUG MARKET
- OVERVIEW OF HEMATOLOGICAL CANCERS
- TABLE 87 OVERVIEW OF MAJOR HEMATOLOGICAL MALIGNANCIES
- TABLE 88 MDS DRUG COMPARISON
- HEMATOLOGICAL DRUG MARKET BY INDICATION
- TABLE 89 HEMATOLOGICAL CANCER EPIGENETIC DRUGS, BY INDICATION, THROUGH 2014 ($ MILLIONS)
- HDAC Hematological Drug Market
- TABLE 90 HDAC HEMATOLOGICAL CANCER EPIGENETIC DRUGS, BY INDICATION, THROUGH 2014 ($ MILLIONS)
- TABLE 91 COMPARISON OF THE PTCL DRUGS, FOLYTYN AND ISTODAX
- DNMT Hematological Drug Market
- TABLE 92 DNMT HEMATOLOGICAL CANCER EPIGENETIC DRUGS, BY INDICATION, THROUGH 2014 ($ MILLIONS)
- CHAPTER SIXTEEN: CELL THERAPY ASSAYS MARKETS
- TABLE 93 EPIGENETIC CELL THERAPIES MARKETS, BY APPLICATION, THROUGH 2014 ($ MILLIONS)
- CHAPTER SEVENTEEN: GEOGRAPHICAL MARKETS
- TABLE 94 EPIGENOMIC RESEARCH TOOLS MARKETS, BY
- GEOGRAPHY, THROUGH 2014 ($ MILLIONS)
- TABLE 95 EPIGENOMIC DIAGNOSTICS MARKETS, BY GEOGRAPHY, THROUGH 2014 ($ MILLIONS)
- TABLE 96 NUMBER OF HOSPITALS AND CLINICS, BY GEOGRAPHICAL REGION
- TABLE 97 EPIGENOMIC PHARMACEUTICALS MARKETS, BY GEOGRAPHY, THROUGH 2014 ($ MILLIONS)
- TABLE 98 EPIGENOMIC CELL THERAPIES MARKETS, BY GEOGRAPHY, THROUGH 2014 ($ MILLIONS)
- CHAPTER EIGHTEEN: COMPETITOR AND INDUSTRY DYNAMICS
- RESEARCH TOOLS
- TABLE 99 SCOPE OF EPIGENOMIC RESEARCH TOOLS SUPPLIERS
- FIGURE 36 CHIP-GRADE ANTIBODY SUPPLIER MARKET SHARES, 2009 (%)
- DIAGNOSTICS
- SKILL SET FOR BIOTECHNOLOGY DIAGNOSTICS COMPANIES
- SHIFTING PARADIGM IN DIAGNOSTICS
- IN-VITRO DIAGNOSTICS COMPETITORS
- TABLE 100 IN-VITRO DIAGNOSTICS COMPETITORS
- TABLE 101 STRATEGIC ALLIANCE STATUS FOR BIOTECHNOLOGY EPIGENETICS DIAGNOSTICS FIRMS
- TABLE 102 COMPETITIVE LANDSCAPE FOR MOLECULAR DIAGNOSTICS TECHNOLOGIES
- EPIGENETIC DRUGS INDUSTRY
- TABLE 103 RELATIVE STRATEGIC POSITION FOR EPIGENOMIC DRUG COMPANIES
- FIGURE 37 EPIGENOMIC DRUG COMPANY MARKET SHARES, 2009
- EPIGENOMIC INDUSTRY STRATEGIC ALLIANCES
- TABLE 104 EPIGENOMICS STATEGIC ALLIANCES: 2007-2010
- EPIGENOMICS INDUSTRY ACQUISITIONS
- TABLE 105 EPIGENOMICS INDUSTRY ACQUISITIONS, 2007-2010
- CHAPTER NINETEEN: PATENTS
- EPIGENOMICS PATENT ACTIVITY
- FIGURE 38 NUMBER OF EPIGENOMICS PATENTS, BY YEAR, 2000-2009
- FIGURE 39 NUMBER OF EPIGENOMICS PATENTS, BY GEOGRAPHY, 2000-2009
- RESEARCH TOOLS AND DIAGNOSTICS PATENT ACTIVITY
- TABLE 106 EPIGENOMICS AG RESEARCH TOOLS PATENT COVERAGE
- FIGURE 40 BIOTECHNOLOGY DIAGNOSTICS PATENTS, BY COMPANY (%)
- TABLE 107 PATENT STATUS FOR BIOTECHNOLOGY DIAGNOSTICS COMPANIES
- PHARMACEUTICALS PATENTS ACTIVITY
- TABLE 108 HDAC INHIBITOR PATENT CLAIMS, 2004-2006
- FIGURE 41 NUMBER OF EPIGENOMICS DRUG PATENTS, BY TECHNOLOGY CLASS AND GEOGRAPHY
- FIGURE 42 NUMBER OF HDAC INHIBITOR PATENTS, BY COMPANY AND GEOGRAPHY
- FIGURE 43 NUMBER OF DNMT INHIBITOR PATENTS, BY COMPANY AND GEOGRAPHY
- PATENT CASE STUDIES
- CHAPTER TWENTY: COMPANY PROFILES
- ABBOTT LABORATORIES
- ABCAM PLC.
- ACCESS PHARMACEUTICALS
- ACETYLON PHARMACEUTICALS
- ACTIVE MOTIF
- AFFYMETRIX, INC.
- TABLE 109 AFFYMETRIX STRATEGIC ALLIANCES
- AGILENT TECHNOLOGIES, INC.
- ARNO THERAPEUTICS, INC.
- ARUP LABORATORIES, INC
- ASTELLAS PHARMA, INC.
- BAYER AG
- BIOFIELD CORP.
- BIOSERVE BIOTECHNOLOGIES, LTD.
- BIOVISION
- CELGENE CORPORATION
- CELLARTIS AB
- CELLCENTRIC LTD.
- CELLERON THERAPEUTICS LTD.
- CELLZOME AG
- CHIPSCREEN BIOSCIENCES LTD.
- CHROMA THERAPEUTICS LTD.
- CLAVIS PHARMA ASA
- TABLE 110 CLAVIS PHARMA DRUG PIPELINE
- CONSTELLATION PHARMACEUTICALS
- CRYSTAL GENOMICS, INC.
- CURIS
- EISAI CO. LTD.
- EPIGENOMICS AG
- EPIGENTEK
- EPITHERAPEUTICS
- ELIXIR PHARMACEUTICALS, INC.
- ENVIVO PHARMACEUTICALS
- EOS SPA
- EPIONTIS GMBH
- EPIZYME, INC.
- ES CELL INTERNATIONAL PTE LTD
- EXONHIT THERAPEUTICS SA
- F. HOFFMANN-LA ROCHE, LTD.
- GENEXTRA S.P.A
- GENPATHWAY, INC.
- GLAXOSMITHKLINE
- HUYA BIOSCIENCE INTERNATIONAL
- ILLUMINA, INC.
- TABLE 111 ILLUMINA SEQUENCING TECHNOLOGY SPACE
- IMAGENES GMBH
- INTERNATIONAL DRUG DISCOVERY INSTITUTE
- ITALFARMACO SPA
- JOHNSON & JOHNSON
- KARUS THERAPEUTICS LTD.
- LABORATORY CORPORATION OF AMERICA HOLDINGS
- LES LABORATOIRES SERVIER
- LIFE TECHNOLOGIES INC.
- MERCK KGAA
- MERCK & CO. INC.
- METHYLGENE
- TABLE 112 METHYLGENE HDAC INHIBITOR PRODUCT PIPELINE
- MILLIPORE
- NATUREWISE BIOTECH & MEDICALS CORP.
- NOVARTIS
- ONCOLYS BIOPHARMA INC.
- ONCOMETHYLOME SCIENCES S.A.
- TABLE 113 ONCOMETHYLOME DNA METHYLATION DIAGNOSTICS PIPELINE
- ORCHID CHEMICALS & PHARMACEUTICALS LIMITED
- ORION GENOMICS
- TABLE 114 ORION STRATEGIC ALLIANCES
- TABLE 115 ORION EPIGENETIC DIAGNOSTICS PIPELINE
- ORTHO BIOTECH
- PACIFIC BIOSCIENCES
- PHARMACYCLICS
- PROGEN PHARMACEUTICALS LTD.
- PROGNOSDX HEALTH, INC.
- QUEST DIAGNOSTICS
- ROCHE LIFE SCIENCES
- QIAGEN GMBH
- RAINDANCE TECHNOLOGIES
- REACTION BIOLOGY CORP.
- REPLIGEN CORPORATION
- RUBICON GENOMICS
- S*BIO PTE LTD
- TABLE 116 S*BIO HDAC INHIBITOR DRUG PIPELINE
- SCHERING PLOUGH CORPORATION
- SCOTTISH BIOMEDICAL LTD.
- SEQUENOM, INC.
- SEQWRIGHT
- SUPERGEN, INC.
- SYNDAX PHARMACEUTICALS, INC.
- TABLE 117 ENTINOSTAT CLINICAL TRIALS SUMMARY STATUS
- SYSMEX CORPORATION
- TAIHO PHARMACEUTICALS
- TAKEDA PHARMACEUTICAL COMPANY LIMITED
- TARGECEPT, INC.
- THEREPI INC
- TOPOTARGET A/S
- TABLE 118 TOPOTARGET’S HDAC INHIBITOR PATENT PORTFOLIO
- VALIBIO SA
- VALIRX
- VERIDEX LLC
- ZYMO RESEARCH
- LIST OF TABLES
- SUMMARY TABLE GLOBAL VALUE OF EPIGENOMIC PRODUCTS, BY
- APPLICATION, THROUGH 2014 ($ MILLIONS)
- TABLE 1 GENOMICS PLATFORMS
- TABLE 2 TECHNOLOGY SCOPE OF THIS REPORT
- TABLE 3 GLOBAL VALUE OF EPIGENOMIC PRODUCTS, BY
- APPLICATION, THROUGH 2014 ($ MILLIONS)
- TABLE 4 HISTORICAL OVERVIEW OF EPIGENOMICS
- TABLE 5 EPIGENOMICS INDUSTRY KEY COMPANIES
- TABLE 6 EPIGENETIC ANALYSIS TECHNOLOGIES
- TABLE 7 STATUS OF DNA METHYLATION AND HISTONE ANALYSIS
- TECHNOLOGIES
- TABLE 8 BIOLOGICAL ROLES OF DNA METHYLATION
- TABLE 9 DESCRIPTION OF CPG ISLANDS
- TABLE 10 HDAC ENZYMES CLASSES
- TABLE 11 MECHANISMS FOR INAPPROPRIATE METHYLATION AND
- ACETYLATION
- TABLE 12 DNA METHYLATION ANALYSIS ASSAYS
- TABLE 13 EMERGING DNA METHYLATION TECHNOLOGIES
- TABLE 14 ACROYNMS FOR DNA METHYLATION TECHNOLOGIES
- TABLE 15 DNA METHYLATION TECHNOLOGIES BY COVERAGE AND
- THROUGHPUT
- TABLE 16 EXAMPLES OF DNA METHYLATION ASSAYS
- TABLE 17 METHYLATION RECOGNITION TECHNOLOGIES
- TABLE 18 DNA METHYLATION ANALYSIS TECHNIQUES BY GENOME
- RESOLUTION
- TABLE 19 CHIP ASSAYS
- TABLE 20 TECHNOLOGIES FOR MAPPING GENOMIC LOCATION OF
- CHROMATIN PROTEINS AND ENZYMES
- TABLE 21 MICROARRAY TYPES
- TABLE 22 COMPARISON OF DNA AND PROTEIN MICROARRAY
- TECHNOLOGIES
- TABLE 23 MICROARRAY GENOME CONTENT
- TABLE 24 DNA MICROARRAY PLATFORM FEATURES
- TABLE 25 DNA MICROARRAY PLATFORM COMPARISON FOR MAJOR
- MANUFACTURERS
- TABLE 26 ROLE OF BIOMARKERS IN CLINICAL TRIAL DESIGN
- TABLE 27 BIOLOGICAL RATIONALE FOR DNA METHYLATION
- CANCER BIOMARKERS
- TABLE 28 CANCER-RELATED CELL PATHWAYS AND GENES
- AFFECTED BY HYPER-METHYLATION
- TABLE 29 CANCER-RELATED EPIGENETIC CHANGES
- TABLE 30 COMPARISON OF KEY CANCER BIOMARKER
- TECHNOLOGY PLATFORMS
- TABLE 31 PUBLISHED DNA METHYLATION BIOMARKER GENES FOR
- CANCERS
- TABLE 32 DIFFERENTIALLY METHYLATED GENES IN NEUROLOGIC
- AND CARDIOVASCULAR DISORDERS
- TABLE 33 DNA METHYLATION ANALYSIS TECHNOLOGIES IN
- BIOMARKER DISCOVERY
- TABLE 34 TECHNICAL HURDLES FOR DEVELOPMENT OF
- METHYLATION EPIGENETIC CANCER BIOMARKERS
- TABLE 35 EPIGENETIC GENES ALTERED IN HUMAN CANCERS
- TABLE 36 STATUS OF INHIBITORS OF EPIGENETIC ENZYMES
- TARGETING HISTONES
- TABLE 37 HDAC INHIBITOR CLASSES AND RELATIVE POTENCY
- TABLE 38 HDAC INHIBITOR DRUG TECHNOLOGY TRENDS
- TABLE 39 HDAC INHIBITOR CLASS I AND II SELECTIVITY
- TABLE 40 DRUG CLASSES THAT CAN BE USED IN COMBINATION
- WITH HDAC INHIBITORS
- TABLE 41 FUTURE CHALLENGES FOR EPIGENETIC DRUG
- DEVELOPMENT
- TABLE 42 TECHNOLOGY OPPORTUNITIES IN SOMATIC CELL
- NUCLEAR TRANSFER
- TABLE 43 REGIONAL EPIGENOMICS INITIATIVES
- TABLE 44 COMMERCIAL MOLECULAR DIAGNOSTIC PLATFORMS
- FOR TISSUE OF ORIGIN TESTS
- TABLE 45 COMMERCIAL LANDSCAPE FOR HPV TESTS
- TABLE 46 CURRENT SCREENING AND DIAGNOSTICS TESTS FOR
- COLORECTAL CANCER
- TABLE 47 ACCURACY OF EXISTING COLORECTAL SCREENING
- TESTS
- TABLE 48 COMMERCIAL LANDSCAPE FOR COLORECTAL
- MOLECULAR TESTS
- TABLE 49 COMPETITIVE SITUATION FOR CONVENTIONAL AND
- MOLECULAR COLON CANCER SCREENING TESTS
- TABLE 50 OVARIAN CANCER SCREENING TESTS
- TABLE 51 OVARIAN CANCER DIAGNOSTIC TEST STATUS
- TABLE 52 REQUIREMENTS FOR AN EPIGENETICS BISULFITE
- DIAGNOSTIC ASSAY
- TABLE 53 EPIGENETIC DIAGNOSTICS DEVELOPMENT PIPELINE
- TABLE 54 APPROVED EPIGENETIC DRUGS
- TABLE 55 NEXT GENERATION EPIGENETIC DRUGS
- TABLE 56 EPIGENETIC DRUG NOMENCLATURE TABLE
- TABLE 57 HDAC INHIBITOR CLINICAL TRIALS SUMMARY
- TABLE 58 MBCD0103 INHIBITS SELECTED HDAC ENZYMES
- TABLE 59 DNMT INHIBITOR CLINICAL TRIALS SUMMARY
- TABLE 60 EPIGENETIC NON-CANCER DRUG LANDSCAPE
- TABLE 61 FORCES DRIVING EPIGENOMICS INDUSTRY GROWTH
- TABLE 62 STIMULUS FUNDING ALLOCATED TO UNITED STATES
- SCIENCE SPENDING
- TABLE 63 GLOBAL VALUE OF EPIGENOMIC PRODUCTS, BY
- APPLICATION, THROUGH 2014 ($ MILLIONS)
- TABLE 64 GLOBAL VALUE OF EPIGENOMIC PRODUCTS, BY
- GEOGRAPHY, THROUGH 2014 ($ MILLIONS)
- TABLE 65 GLOBAL VALUE OF EPIGENOMIC ANALYSIS RESEARCH
- TOOLS, BY PRODUCT TYPE, THROUGH 2014 ($ MILLIONS)
- TABLE 66 GLOBAL VALUE OF EPIGENOMICS RESEARCH TOOLS
- KITS, BY TECHNOLOGY, THROUGH 2014 ($ MILLION)
- TABLE 67 GLOBAL VALUE OF EPIGENOMIC ANALYSIS KITS, BY
- FORMAT, THROUGH 2014 ($ MILLIONS)
- TABLE 68 GLOBAL VALUE OF DNA METHYLATION RESEARCH
- TOOLS KITS, BY ANALYSIS OBJECTIVE, THROUGH 2014 ($
- MILLIONS)
- TABLE 69 GLOBAL VALUE OF DNA METHYLATION RESEARCH
- TOOLS KITS, BY TECHNOLOGY, THROUGH 2014 ($ MILLIONS)
- TABLE 70 GLOBAL VALUE OF DNA METHYLATION SINGLE LOCI
- RESEARCH TOOLS KITS, BY TECHNOLOGY, THROUGH 2014 ($
- MILLIONS)
- TABLE 71 GLOBAL VALUE OF DNA METHYLATION GENOME-WIDE
- RESEARCH TOOLS KITS BY TECHNOLOGY, THROUGH 2014 ($
- MILLIONS)
- TABLE 72 GLOBAL VALUE OF HISTONE ANALYSIS KITS, BY
- TECHNOLOGY FORMAT, THROUGH 2014 ($ MILLIONS)
- TABLE 73 GLOBAL VALUE OF EPIGENOMIC MICROARRAYS, BY
- APPLICATION, THROUGH 2014 ($ MILLIONS)
- TABLE 74 GLOBAL VALUE OF RESEARCH TOOLS EPIGENOMIC
- REAGENTS, BY TECHNOLOGY, THROUGH 2014 ($ MILLIONS)
- TABLE 75 VALUE OF GLOBAL MOLECULAR DIAGNOSTICS
- PRODUCTS, BY APPLICATION, THROUGH 2014 ($ MILLIONS)
- TABLE 76 PROJECTED CHANGE IN AGE 65-PLUS POPULATION BY
- REGION (%)
- TABLE 77 U.S. CANCER INCIDENCE AND ESTIMATED TREATMENT
- DECISIONS, 2009
- TABLE 78 GLOBAL VALUE OF EPIGENETIC DIAGNOSTIC ASSAYS, BY
- APPLICATION, THROUGH 2014 ($ MILLIONS)
- TABLE 79 GLOBAL VALUE OF EPIGENETIC DIAGNOSTIC ASSAYS, BY
- CANCER INDICATION, THROUGH 2014 ($ MILLIONS)
- TABLE 80 GLOBAL VALUE OF EPIGENETIC DRUGS, BY CANCER
- INDICATION, THROUGH 2014 ($ MILLIONS)
- TABLE 81 GLOBAL VALUE OF EPIGENETIC DRUGS, BY DRUG CLASS,
- THROUGH 2014 ($ MILLIONS)
- TABLE 82 SUMMARY OF HDAC INHIBITOR STRATEGIC
- OPPORTUNITIES FOR CANCER TREATMENT
- TABLE 83 GLOBAL VALUE OF HDAC INHIBITOR DRUGS, BY
- INDICATION, THROUGH 2014 ($ MILLIONS)
- TABLE 84 GLOBAL VALUE OF HDAC INHIBITOR DRUGS, BY
- TECHNOLOGY, THROUGH 2014 ($ MILLIONS)
- TABLE 85 GLOBAL VALUE OF DNMT INHIBITOR DRUGS, BY
- INDICATION, THROUGH 2014 ($ MILLIONS)
- TABLE 86 GLOBAL VALUE OF DNMT INHIBITOR DRUGS, BY
- TECHNOLOGY, THROUGH 2014 ($ MILLIONS)
- TABLE 87 OVERVIEW OF MAJOR HEMATOLOGICAL MALIGNANCIES
- TABLE 88 MDS DRUG COMPARISON
- TABLE 89 HEMATOLOGICAL CANCER EPIGENETIC DRUGS, BY
- INDICATION, THROUGH 2014 ($ MILLIONS)
- TABLE 90 HDAC HEMATOLOGICAL CANCER EPIGENETIC DRUGS, BY
- INDICATION, THROUGH 2014 ($ MILLIONS)
- TABLE 91 COMPARISON OF THE PTCL DRUGS, FOLYTYN AND
- ISTODAX
- TABLE 92 DNMT HEMATOLOGICAL CANCER EPIGENETIC DRUGS, BY
- INDICATION, THROUGH 2014 ($ MILLIONS)
- TABLE 93 EPIGENETIC CELL THERAPIES MARKETS, BY
- APPLICATION, THROUGH 2014 ($ MILLIONS)
- TABLE 94 EPIGENOMIC RESEARCH TOOLS MARKETS, BY
- GEOGRAPHY, THROUGH 2014 ($ MILLIONS)
- TABLE 95 EPIGENOMIC DIAGNOSTICS MARKETS, BY GEOGRAPHY,
- THROUGH 2014 ($ MILLIONS)
- TABLE 96 NUMBER OF HOSPITALS AND CLINICS, BY
- GEOGRAPHICAL REGION
- TABLE 97 EPIGENOMIC PHARMACEUTICALS MARKETS, BY
- GEOGRAPHY, THROUGH 2014 ($ MILLIONS)
- TABLE 98 EPIGENOMIC CELL THERAPIES MARKETS, BY
- GEOGRAPHY, THROUGH 2014 ($ MILLIONS)
- TABLE 99 SCOPE OF EPIGENOMIC RESEARCH TOOLS SUPPLIERS
- TABLE 100 IN-VITRO DIAGNOSTICS COMPETITORS
- TABLE 101 STRATEGIC ALLIANCE STATUS FOR BIOTECHNOLOGY
- EPIGENETICS DIAGNOSTICS FIRMS
- TABLE 102 COMPETITIVE LANDSCAPE FOR MOLECULAR
- DIAGNOSTICS TECHNOLOGIES
- TABLE 103 RELATIVE STRATEGIC POSITION FOR EPIGENOMIC
- DRUG COMPANIES
- TABLE 104 EPIGENOMICS STATEGIC ALLIANCES: 2007-2010
- TABLE 105 EPIGENOMICS INDUSTRY ACQUISITIONS, 2007-2010
- TABLE 106 EPIGENOMICS AG RESEARCH TOOLS PATENT COVERAGE
- TABLE 107 PATENT STATUS FOR BIOTECHNOLOGY DIAGNOSTICS
- COMPANIES
- TABLE 108 HDAC INHIBITOR PATENT CLAIMS, 2004-2006
- TABLE 109 AFFYMETRIX STRATEGIC ALLIANCES
- TABLE 110 CLAVIS PHARMA DRUG PIPELINE
- TABLE 111 ILLUMINA SEQUENCING TECHNOLOGY SPACE
- TABLE 112 METHYLGENE HDAC INHIBITOR PRODUCT PIPELINE
- TABLE 113 ONCOMETHYLOME DNA METHYLATION DIAGNOSTICS
- PIPELINE
- TABLE 114 ORION STRATEGIC ALLIANCES
- TABLE 115 ORION EPIGENETIC DIAGNOSTICS PIPELINE
- TABLE 116 S*BIO HDAC INHIBITOR DRUG PIPELINE
- TABLE 117 ENTINOSTAT CLINICAL TRIALS SUMMARY STATUS
- TABLE 118 TOPOTARGET’S HDAC INHIBITOR PATENT PORTFOLIO
- LIST OF FIGURES
- SUMMARY FIGURE GLOBAL VALUE OF EPIGENOMIC PRODUCTS, BY
- APPLICATION, 2008-2014 ($ MILLIONS)
- FIGURE 1 EPIGENOMICS: A NEW PARADIGM
- FIGURE 2 ACTIVE CANCER EPIGENETIC DRUG CLINICAL TRIALS, BY
- PHASE AND INDICATION, JANUARY 2010
- FIGURE 3 EPIGENETIC PROCESSES CAN GENERATE ABNORMAL
- CELLS DURING CELL DEVELOPMENT
- FIGURE 4 UPSTREAM AND DOWNSTREAM STEPS IN EPIGENETIC
- ANALYSIS WORKFLOW
- FIGURE 5 EPIGENETIC CHANGES TO DNA AFFECT GENE
- EXPRESSION
- FIGURE 6 ACETYLATION OF HISTONE TAIL REGIONS
- FIGURE 7 HISTONE ACETYLATION AND METHYLATION ENZYMES
- FIGURE 8 METHYLATED DNA ANALYSIS WORKFLOW
- FIGURE 9 ANALYSIS OF DNA METHYLATION BY RESTRICTION
- ENZYMES
- FIGURE 10 BISULFITE CONVERSION OF DNA
- FIGURE 11 WORKFLOW SCHEMATIC FOR CHIP PLATFORMS
- FIGURE 12 MICROARRAY FEATURE DENSITY
- FIGURE 13 MICROARRAY RESOLUTION
- FIGURE 14 MICROARRAYS ENHANCE MULTIPLEX CAPABILITIES OF
- EPIGENETICS ASSAYS
- FIGURE 15 DNA SEQUENCING PLATFORMS
- FIGURE 16 NEXT GENERATION SEQUENCING TECHNOLOGIES
- WORKFLOW OVERVIEW
- FIGURE 17 HISTONE DEACETYLASE REACTION
- FIGURE 18 CHEMICAL STRUCTURE OF TRICHOSTATIN A, A
- HYDROXAMATE CLASS HDAC INHIBITOR
- FIGURE 19 PHENYLBUTYRIC ACID, AN ALIPHATIC ACID CLASS
- HDAC INHIBITOR
- FIGURE 20 APICIDIN A, A CYCLIC TETRAPEPTIDE CLASS HDAC
- INHIBITOR
- FIGURE 21 ENTINOSTAT, A BENZAMIDE CLASS HDAC INHIBITOR
- FIGURE 22 DISEASE HDAC ISOFORM GENE EXPRESSION PROFILE
- FIGURE 23 COMMON STRUCTURAL COMPONENT MOTIFS OF
- VORINOSTAT
- FIGURE 24 LEAD DNMT INHIBITOR COMPOUNDS
- FIGURE 25 SOMATIC CELL NUCLEAR TRANSFER
- FIGURE 26 EPIGENETIC PROGRAMMING OF STEM CELLS
- FIGURE 27 CANCER SCREENING OPPORTUNITY MATRIX FOR
- MOLECULAR DIAGNOSTICS
- FIGURE 28 NEW EPIGENETIC SCREENING PARADIGM
- FIGURE 29 SENSITIVITY AND SPECIFICITY
- FIGURE 30 ACTIVE CANCER EPIGENETIC DRUG CLINICAL TRIALS,
- BY DRUG CLASS AND CANCER TYPE, JANUARY 2010
- FIGURE 31 ACTIVE CANCER EPIGENETIC DRUG CLINICAL TRIALS,
- BY PHASE AND INDICATION, JANUARY 2010
- FIGURE 32 CURRENT EPIGENETIC CANCER DRUG CLINICAL
- TRIALS, BY DRUG AND TRIAL TYPE, JANUARY 2010
- FIGURE 33 ACTIVE EPIGENETIC CANCER DRUG CLINICAL TRIALS,
- BY CLINICAL PHASE AND TRIAL TYPE, JANUARY 2010
- FIGURE 34 GROWTH IN SCIENTIFIC PUBLICATIONS RELATED TO
- EPIGENETICS (NUMBER OF PUBLICATIONS)
- FIGURE 35 ANNUAL NIH FUNDING BUDGET, 2000-2009 ($ MILIONS)
- FIGURE 36 CHIP-GRADE ANTIBODY SUPPLIER MARKET SHARES,
- 2009 (%)
- FIGURE 37 EPIGENOMIC DRUG COMPANY MARKET SHARES, 2009
- FIGURE 38 NUMBER OF EPIGENOMICS PATENTS, BY YEAR, 2000-
- 2009
- FIGURE 39 NUMBER OF EPIGENOMICS PATENTS, BY GEOGRAPHY,
- 2000-2009
- FIGURE 40 BIOTECHNOLOGY DIAGNOSTICS PATENTS, BY COMPANY
- (%)
- FIGURE 41 NUMBER OF EPIGENOMICS DRUG PATENTS, BY
- TECHNOLOGY CLASS AND GEOGRAPHY
- FIGURE 42 NUMBER OF HDAC INHIBITOR PATENTS, BY COMPANY
- AND GEOGRAPHY
- FIGURE 43 NUMBER OF DNMT INHIBITOR PATENTS, BY COMPANY
- AND GEOGRAPHY
For full details, please email keithw@cmsinfo.com
Top of Page
Buy now!
Top of Page
|
|